FAF1 expression based on
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Comparison | Statistical significance |
Normal-vs-Primary | 1.64157576421076E-12 |
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Stage1 |
1.95440330585939E-11 |
Normal-vs-Stage2 |
6.445600E-04 |
Normal-vs-Stage3 |
N/A |
Normal-vs-Stage4 |
1.291520E-02 |
Stage1-vs-Stage2 |
2.639400E-01 |
Stage1-vs-Stage3 |
N/A |
Stage1-vs-Stage4 |
1.178860E-03 |
Stage2-vs-Stage3 |
N/A |
Stage2-vs-Stage4 |
9.381600E-02 |
Stage3-vs-Stage4 |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Caucasian |
2.482014593852E-12 |
Normal-vs-AfricanAmerican |
7.287800E-02 |
Normal-vs-Asian |
7.856500E-02 |
Caucasian-vs-AfricanAmerican |
1.757610E-02 |
Caucasian-vs-Asian |
7.341600E-01 |
AfricanAmerican-vs-Asian |
7.843900E-02 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Male |
9.92299999946766E-08 |
Normal-vs-Female |
2.89029999933632E-08 |
Male-vs-Female |
6.991400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Patient BMI information is not available for 1 sample.
Descriptions |
Normal weight |
BMI greater than equal to 18.5 and BMI less than 25 |
Extereme weight |
BMI greater than equal to 25 and BMI less than 30 |
Obese |
BMI greater than equal to 30 and BMI less than 40 |
Extreme Obese |
BMI greater than 40 |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Normal_Weight |
1.556240E-03 |
Normal-vs-Extreme_Weight |
8.96630000246645E-08 |
Normal-vs-Obese |
9.813200E-04 |
Normal-vs-Extreme_Obese |
N/A |
Normal_Weight-vs-Extreme_Weight |
1.578000E-01 |
Normal_Weight-vs-Obese |
4.601800E-01 |
Normal_Weight-vs-Extreme_Obese |
N/A |
Extreme_Weight-vs-Obese |
5.969600E-01 |
Extreme_Weight-vs-Extreme_Obese |
N/A |
Obese-vs-Extreme_Obese |
N/A |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Age(21-40Yrs) |
5.89909999959559E-07 |
Normal-vs-Age(41-60Yrs) |
1.789900E-04 |
Normal-vs-Age(61-80Yrs) |
3.91429999524462E-09 |
Normal-vs-Age(81-100Yrs) |
9.234300E-02 |
Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.823200E-01 |
Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.792600E-01 |
Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.505200E-01 |
Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.715600E-01 |
Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.568600E-01 |
Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.788000E-01 |
|
|
CHOL : Cholangiocarcinoma
Subtype descriptions |
Grade 1 | Well differentiated (low grade) |
Grade 2 | Moderately differentiated (intermediate grade) |
Grade 3 | Poorly differentiated (high grade) |
Grade 4 | Undifferentiated (high grade) |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-Grade 1 |
N/A |
Normal-vs-Grade 2 |
9.077800E-01 |
Normal-vs-Grade 3 |
8.088400E-01 |
Normal-vs-Grade 4 |
1.000000E+00 |
Grade 1-vs-Grade 2 |
N/A |
Grade 1-vs-Grade 3 |
N/A |
Grade 1-vs-Grade 4 |
N/A |
Grade 2-vs-Grade 3 |
7.828600E-01 |
Grade 2-vs-Grade 4 |
9.077800E-01 |
Grade 3-vs-Grade 4 |
8.088400E-01 |
|
|
CHOL : Cholangiocarcinoma *
Please note that low number(<10) of normal samples considered.
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 5 samples.
pathologic_N descriptions |
N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
Comparison |
Statistical significance |
Normal-vs-N0 |
1.07980291375043E-11 |
Normal-vs-N1 |
1.064130E-02 |
N0-vs-N1 |
1.349960E-01 |
|
|